万基遗传 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period ended March31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period fromto Commission file number:0-26642 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) Not applicable (Former name or former address, if changed since last report) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐ Accelerated filerSmaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No As of May1, 2026, the registrant had 94,448,210 shares of $0.01 par value common stock outstanding. MYRIAD GENETICS, INC. INDEX TO FORM 10-Q PART I - Financial Information Item 1.Financial StatementsCondensed Consolidated Balance Sheets as ofMarch31, 2026andDecember31, 2025(unaudited)4Condensed Consolidated Statements of Operations for thethree months ended March 31, 2026 and 2025(unaudited)5Condensed Consolidated Statements of Comprehensive Income(Loss) for thethree months ended March 31,2026 and2025(unaudited)6Condensed Consolidated Statements of Stockholders’ Equity for thethree months ended March 31, 2026and2025(unaudited)7Condensed Consolidated Statements of Cash Flows for thethree months ended March 31, 2026and2025(unaudited)8Notes to Condensed Consolidated Financial Statements (unaudited)9Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures26 PART II - Other InformationItem 1.Legal Proceedings27Item 1A.Risk Factors27Item 2.Unregistered Sales of Equity Securities and Use of Proceeds27Item 3.Defaults Upon Senior Securities27Item 4.Mine Safety Disclosures27Item 5.Other Information27Item 6.Exhibits28Signatures29 PART I - Financial Information Item 1.Financial Statements. MYRIAD GENETICS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (unaudited) (in millions) MYRIAD GENETICS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (unaudited) (in millions, except per share amounts) MYRIAD GENETICS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) (in millions) Net loss See accompanying notes to Condensed Consolidated Financial Statements. MYRIAD GENETICS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (in millions) MYRIAD GENETICS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (unaudited) (in millions) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1.BASIS OF PRESENTATION Myriad Genetics, Inc. (together with its subsidiaries, the “Company” or “Myriad”) is a leading molecular diagnostics and precisionmedicine company committed to advancing health and well-being for all. The Company develops and commercializes molecular teststhat help patients and providers uncover genetic insights. Myriad tests assess the risk of developing disease or disease progression andguide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlierdetection, enable more precise treatment and contribute to lowering healthcare costs. The Company’s principal executive office islocated in Salt Lake City, Utah. The accompanying Condensed Consolid